• Home
• Defective Drug Index
• About A Drug Recall
• Contact A Defective Drug Lawyer

We Can Help.

Remicade increases cancer risk

Remicade News

Remicade Causes Cancer, Infection

May 17, 2006 - A Mayo Clinic study indicates that arthritis drugs Remicade triple the risk of many types of cancer and double the risk of serious infections . While the overall risk of developing cancer from these drugs remains small, the risk can vary widely by patient.

Click Here Read About This New Study

 

Remicade increases cancer risk, second label change in three months issued

October 8, 2004

Johnson & Johnson is warning doctors that people taking its rheumatoid arthritis drug Remicade may have a higher risk of blood cancer called lymphoma. The warning of a three-fold increase among Remicade patients contracting lymphoma compared to the normal population will be added to the drug's package insert.

J&J has said it will send letters to doctors on October 11, informing them of the new Remicade safety warnings. This will be the second Remicade labeling safety change within three months. In August, the Remicade labeling was changed to include the risk of certain blood-related disorders such as leucopenia and thrombocytopenia.

Remicade belongs to the class of drugs that block an inflammation causing protein called tumor necrosis factor, which includes the drugs Enbrel and Humira. Tuberculosis safety concerns have also recently arisen when taking this class of drug.

For more information on Remicade side effects, please contact us.

More Recent Defective Drug News

• Reglan
• Raptiva
• Yaz Birth Control
• Nuvaring
• Duragesic Patch
• Heparin